Health Technology Assessment
As the Kingdom of Saudi Arabia (KSA) implements new health technology assessment (HTA) requirements, understanding how economic evaluations may influence future pricing and reimbursement decisions is becoming increasingly important. This poster explores early perspectives from KSA formulary decision-makers on the anticipated role of HTA in market access, with a particular focus on rare diseases.
Findings suggest that cost-effectiveness, disease burden, comparative effectiveness, and local evidence are expected to be key drivers of decision-making under the new framework. The research highlights the growing importance of early evidence planning and local data generation as manufacturers adapt to KSA’s evolving value-based healthcare environment.
